Publications 2022

Aamdal E, Jacobsen KD, Straume O, Kersten C, Herlofsen O, Karlsen J, Hussain I, Amundsen A, Dalhaug A, Nyakas M, Schuster C, Hagene KT, Holmsen K, Russnes HG, Skovlund E, Kaasa S, Aamdal S, Kyte JA, Guren TK (2022)
Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up
Int. J. Cancer, 150 (1), 100-111
DOI 10.1002/ijc.33768

Publications 2020

Brunsvig PF, Guren TK, Nyakas M, Steinfeldt-Reisse CH, Rasch W, Kyte JA, Juul HV, Aamdal S, Gaudernack G, Inderberg EM (2020)
Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer
Front. Immunol., 11, 572172
DOI 10.3389/fimmu.2020.572172

Kyte JA, Andresen NK, Russnes HG, Fretland SO, Falk RS, Lingjaerde OC, Naume B (2020)
ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer
J. Transl. Med., 18 (1), 269
DOI 10.1186/s12967-020-02421-w

Kyte JA, Rossevold A, Falk RS, Naume B (2020)
ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer
J. Transl. Med., 18 (1), 252
DOI 10.1186/s12967-020-02424-7

Publications 2019

Jabeen S, Espinoza JA, Torland LA, Zucknick M, Kumar S, Haakensen VD, Luders T, Engebraaten O, Borresen-Dale AL, Kyte JA, Gromov P, Naume B, Kristensen V, Gromova I, Tekpli X (2019)
Noninvasive profiling of serum cytokines in breast cancer patients and clinicopathological characteristics
OncoImmunology, 8 (2), e1537691
DOI 10.1080/2162402X.2018.1537691

Kyte JA, Fane A, Pule M, Gaudernack G (2019)
Transient redirection of T cells for adoptive cell therapy with telomerase-specific T helper cell receptors isolated from long term survivors after cancer vaccination
OncoImmunology, 8 (4), e1565236
DOI 10.1080/2162402X.2019.1565236

Tekpli X, Lien T, Rossevold AH, Nebdal D, Borgen E, Ohnstad HO, Kyte JA, Vallon-Christersson J, Fongaard M, Due EU, Svartdal LG, Sveli MAT, Garred O, Frigessi A, Sahlberg KK, Sorlie T, Russnes HG, Naume B, Kristensen VN, Borresen-Dale AL, Schlichting E, Sauer T, Geisler J, Hofvind S, Bathen TF et al. (2019)
An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment
Nat. Commun., 10, 5499
DOI 10.1038/s41467-019-13329-5

Publications 2018

Eide HA, Knudtsen IS, Sandhu V, Londalen AM, Halvorsen AR, Abravan A, Kure EH, Bogsrud TV, Brustugun OT, Kyte JA, Malinen E, Helland A (2018)
Serum cytokine profiles and metabolic tumor burden in patients with non-small cell lung cancer undergoing palliative thoracic radiation therapy
Adv. Radiat. Oncol., 3 (2), 130-138
DOI 10.1016/j.adro.2017.12.007

Jabeen S, Zucknick M, Nome M, Dannenfelser R, Fleischer T, Kumar S, Luders T, Gythfeldt HV, Troyanskaya O, Kyte JA, Borresen-Dale AL, Naume B, Tekpli X, Engebraaten O, Kristensen V (2018)
Serum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumab
OncoImmunology, 7 (11)
DOI 10.1080/2162402X.2018.1457598

Oei VYS, Siernicka M, Graczyk-Jarzynka A, Hoel HJ, Yang WW, Palacios D, Almasbak H, Bajor M, Clement D, Brandt L, Onfelt B, Goodridge J, Winiarska M, Zagozdzon R, Olweus J, Kyte JA, Malmberg KJ (2018)
Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors
Cancer Immunol. Res., 6 (4), 467-480
DOI 10.1158/2326-6066.CIR-17-0207

Publications 2017

Ohnstad HO, Borgen E, Falk RS, Lien TG, Aaserud M, Sveli MAT, Kyte JA, Kristensen VN, Geitvik GA, Schlichting E, Wist EA, Sorlie T, Russnes HG, Naume B (2017)
Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up
Breast Cancer Res., 19, 120
DOI 10.1186/s13058-017-0911-9

Publications 2016

Cairns L, Aspeslagh S, Anichini A, Kyte JA, Blank C, Ascierto P, Rekers N, Straten PT, Awada A (2016)
Cancer immunotherapy: from the lab to clinical applications-Potential impact on cancer centres' organisation
eCancerMedicalScience, 10, 691
DOI 10.3332/ecancer.2016.691

Eide HA, Halvorsen AR, Sandhu V, Fane A, Berg J, Haakensen VD, Kure EH, Brustugun OT, Kiserud CE, Kyte JA, Helland A (2016)
Non-small cell lung cancer is characterised by a distinct inflammatory signature in serum compared with chronic obstructive pulmonary disease
Clin. Transl. Immunol., 5, e109
DOI 10.1038/cti.2016.65

Kyte JA, Gaudernack G, Faane A, Lislerud K, Inderberg EM, Brunsvig P, Aamdal S, Kvalheim G, Walchli S, Pule M (2016)
T-helper cell receptors from long-term survivors after telomerase cancer vaccination for use in adoptive cell therapy
OncoImmunology, 5 (12), e1249090
DOI 10.1080/2162402X.2016.1249090

Kyte JA, Aamdal S, Dueland S, Saeboe-Larsen S, Inderberg EM, Madsbu UE, Skovlund E, Gaudernack G, Kvalheim G (2016)
Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells
OncoImmunology, 5 (11), e1232237
DOI 10.1080/2162402X.2016.1232237

Publications 2015

Almasbak H, Walseng E, Kristian A, Myhre MR, Suso EM, Munthe LA, Andersen JT, Wang MY, Kvalheim G, Gaudernack G, Kyte JA (2015)
Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model
Gene Ther., 22 (5), 391-403
DOI 10.1038/gt.2015.4

Hansen GL, Gaudernack G, Brunsvig PF, Cvancarova M, Kyte JA (2015)
Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination
Cancer Immunol. Immunother., 64 (12), 1609-1621
DOI 10.1007/s00262-015-1766-5

Publications 2014

del Campo AB, Kyte JA, Carretero J, Zinchencko S, Mendez R, Gonzalez-Aseguinolaza G, Ruiz-Cabello F, Aamdal S, Gaudernack G, Garrido F, Aptsiauri N (2014)
Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma
Int. J. Cancer, 134 (1), 102-113
DOI 10.1002/ijc.28338

Publications 2011

Brunsvig PF, Kyte JA, Kersten C, Sundstrum S, Muller M, Nyakas M, Hansen GL, Gaudernack G, Aamdal S (2011)
Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated after Chemoradiotherapy and an 8-Year Update on a Phase I/II Trial
Clin. Cancer Res., 17 (21), 6847-6857
DOI 10.1158/1078-0432.CCR-11-1385

Kyte JA, Gaudernack G, Dueland S, Trachsel S, Julsrud L, Aamdal S (2011)
Telomerase Peptide Vaccination Combined with Temozolomide: A Clinical Trial in Stage IV Melanoma Patients
Clin. Cancer Res., 17 (13), 4568-4580
DOI 10.1158/1078-0432.CCR-11-0184

Publications 2009

Kyte JA (2009)
Cancer vaccination with telomerase peptide GV1001
Expert Opin. Investig. Drugs, 18 (5), 687-694
DOI 10.1517/13543780902897631

Kyte JA, Trachsel S, Risberg B, Straten PT, Lislerud K, Gaudernack G (2009)
Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination
Cancer Immunol. Immunother., 58 (10), 1609-1626
DOI 10.1007/s00262-009-0670-2

Publications 2007

Kyte JA (2007)
Immuno-gene therapy of cancer with tumor-mRNA transfecteddendritic cells
In Series of dissertations submitted to the Faculty of Medicine, University of Oslo, Unipub, Oslo, no. 469, 1 b. (flere pag.)
BIBSYS 070189625, ISBN 978-82-8072-418-2

Kyte JA, Kvalheim G, Lislerud K, Straten PT, Dueland S, Aamdal S, Gaudernack G (2007)
T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells
Cancer Immunol. Immunother., 56 (5), 659-675
DOI 10.1007/s00262-006-0222-y

Publications 2006

Kyte JA, Gaudernack G (2006)
Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells
Cancer Immunol. Immunother., 55 (11), 1432-1442
DOI 10.1007/s00262-006-0161-7

Kyte JA, Mu L, Aamdal S, Kvalheim G, Dueland S, Hauser M, Gullestad HP, Ryder T, Lislerud K, Hammerstad H, Gaudernack G (2006)
Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA
Cancer Gene Ther., 13 (10), 905-918
DOI 10.1038/sj.cgt.7700961